Thin
Metabolic / Dual Agonist
View Product & Quotes
Custom Survodutide CAS 2805997-46-8 - Pakistan Formulation Solutions
Pre-formulation and commercial batch availability with complete DMF documentation, HPLC profiles (>98.5%), and cold-chain air freight protocol directly to Jinnah and Allama Iqbal International Airports.
Analyzing epidemiological pressures, DRAP regulatory mechanisms, and the critical need for localized generic biological manufacturing across the nation's 750+ pharmaceutical manufacturing facilities.
The pharmaceutical sector of the Islamic Republic of Pakistan stands at a historical turning point. Historically anchored upon oral solid dosage (OSD) generics and conventional small-molecule chemistry, the domestic drug manufacturing complex—predominantly concentrated in the industrial corridors of Korangi and SITE (Karachi), Sundar Industrial Estate and Kot Lakhpat (Lahore), and the Rawalpindi-Islamabad twin cities—is now confronting an unprecedented epidemiological transformation. According to the International Diabetes Federation (IDF) Diabetes Atlas, Pakistan harbors over 33 million adults living with diabetes, representing the highest comparative prevalence in the world. Compounded by rampant cardiovascular co-morbidities, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD/NASH), the clinical necessity for modern targeted therapeutics has escalated from an elective luxury to a national health emergency.
Therapeutic peptides, particularly GLP-1 receptor agonists (GLP-1 RAs), dual GIP/GLP-1 agonists, and multi-receptor peptides, represent the standard of care globally. However, the prohibitive retail pricing of imported finished biologicals has created a massive healthcare disparity across Pakistan's private-pay consumer base. Local generic formulation pioneers are rapidly working to reverse-engineer, formulate, and register generic peptide injectables under the regulatory purview of the Drug Regulatory Authority of Pakistan (DRAP). Under the DRAP Act 2012 and stringent Common Technical Document (CTD) filing mandates, local formulators cannot rely on volatile spot-market traders. Sourcing Active Pharmaceutical Ingredients (APIs) requires rigorous vendor auditability, traceability of starting materials, absence of immunogenic impurities, and reproducible stability profiles tailored to withstand the intense subtropical climatic conditions of Zone IVb.
Full CTD dossier support (Module 3: Quality) for Form 5 and Form 7 drug registrations. Complete impurity profiling, host cell residual analyses, and cross-reactivity testing to ensure streamlined clearance by DRAP's Registration Board.
Peptide synthesis protocols optimized for high thermal and hydrolytic stability. Custom salt conversions (Acetate to stable Pamoate or specific counter-ions) designed to endure regional ambient fluctuations during regional transit.
Secured dry-ice and validated cold-chain air freight corridors into Karachi (KHI) and Lahore (LHE) customs terminals, preventing lyophilized peptide cake degradation and irreversible aggregation.
Bridging the technological gap for Pakistan's formulation pipelines through advanced multi-ton chemical synthesis, continuous flow technology, and green solvent engineering.
Globally, the commercial peptide industry has transcended legacy recombinant fermentation constraints. While recombinant manufacturing remains relevant for native insulin analogues, the modern therapeutic landscape belongs to highly modified sequences: lipidated side-chains, alpha-aminoisobutyric acid (Aib) unnatural amino acid substitutions, cyclic bridges, and dual/triple co-agonists. For Pakistani pharmaceutical directors seeking long-term margin resilience, understanding the synthesis route is critical to avoiding post-registration manufacturing bottlenecks.
Our multi-ton facility leverages optimized Fmoc Solid-Phase Peptide Synthesis (Fmoc-SPPS) alongside cutting-edge Liquid-Phase / Hybrid Segment Condensation (LPPS). This hybrid approach enables the synthesis of complex peptides comprising 30 to 45 amino acids (such as Semaglutide, Tirzepatide, Retatrutide, and Survodutide) with exceptional chemical fidelity. By pre-synthesizing high-purity protected peptide fragments in solution phase and subsequently coupling them onto specialized low-loading resins, we systematically eliminate the formation of truncated sequence impurities (n-1 and n-2 deletions) that frequently jeopardize registration dossiers.
Removal of cytotoxic Trifluoroacetic Acid (TFA) salts with pharmaceutically acceptable Acetate or Hydrochloride counter-ions, ensuring total biological tolerability and formulation stability in ready-to-use injectables.
Produced under cleanroom conditions compliant with EU cGMP Class C/A requirements. Stringent control over Bacterial Endotoxins (<10 EU/mg for injectable grades), ensuring safe systemic administration.
Custom-engineered freeze-drying cycles generate robust lyophilized cakes with uniform porosity, moisture contents below 3.0%, and rapid reconstitution characteristics for fill-finish operations.
Transparent volume-tiered cost structures tailored for Pakistani pharmaceutical R&D pilots, validation campaigns, and commercial-scale vial/pen manufacturing.
In Pakistan's competitive pharmaceutical procurement environment, navigating exchange rate dynamics and Letter of Credit (LC) opening regulations requires absolute clarity regarding peptide API pricing structures. Unlike standard small-molecule raw materials quoted in metric tons, peptide pricing is governed by sequence complexity, synthetic length, amino acid modifications (e.g., C-terminal amidation, lipid diacid conjugates), purity specifications, and lot volume.
Below is the standard reference pricing architecture designed for Pakistani pharmaceutical buyers, CDMO partners, and licensed compounding facilities. All quotes represent wholesale B2B pricing, inclusive of Certificate of Analysis (CoA), MS/HPLC reports, and validated temperature-controlled packaging.
| Peptide Molecule | CAS Registry # | Standard Specification | R&D Scale (1g - 10g) | Pilot Batch (50g - 250g) | Commercial Supply (>1,000g) | Primary Pakistani Indication |
|---|---|---|---|---|---|---|
| Survodutide | 2805997-46-8 | Purity >98.0%, Acetate | Contact Desk | Inquire for Tier | Direct Quote | NASH, Fibrosis, Severe Obesity |
| Tesamorelin | 218949-48-5 | Purity >98.5%, Lyophilized | $180 - $260 / g | $110 - $160 / g | Tiered Volume Model | Visceral Adiposity, Endocrine Deficits |
| Semax | 80714-61-0 | Purity >99.0%, Sterile | $45 - $75 / g | $28 - $42 / g | Commercial Scale Contract | Ischemic Stroke, Cognitive Therapeutics |
| GHK-Cu (Copper Peptide) | 89030-95-7 | Purity >99.0%, Deep Blue | $12 - $20 / g | $6 - $9 / g | Bulk Ton/Kg Supply | Cosmeceuticals, Post-Laser Recovery |
| Cargrilintide | 1415456-99-3 | Purity >98.0%, Acetate | $280 - $420 / g | $190 - $290 / g | Commercial Agreement | Dual-therapy Obesity (Amylin analog) |
| Retatrutide | 2381089-83-2 | Purity >98.5%, TFA-Free | $350 - $550 / g | $220 - $340 / g | Custom Scale-Up Quote | Triple GIP/GLP-1/Glucagon Therapy |
| Linaclotide | 851199-59-2 | Purity >98.0%, 3-Disulfide Bridges | $160 - $240 / g | $95 - $150 / g | Commercial OSD Supply | IBS-C, Chronic Idiopathic Constipation |
| Selank | 129954-34-3 | Purity >99.0%, Acetate | $50 - $80 / g | $30 - $45 / g | Long-Term Contract | Generalized Anxiety, Neuro-Immunology |
| Orforglipron | 2212020-52-3 | Purity >98.5%, Small-Mol Non-Peptide | $220 - $350 / g | $140 - $210 / g | Direct Factory Sourcing | Oral Non-Peptide GLP-1 (OSD Solid Tablets) |
| Bremelanotide (PT-141) | 189691-06-3 | Purity >98.5%, Cyclic | $90 - $140 / g | $55 - $85 / g | Volume Contract | Sexual Dysfunction, Melanocortin Receptor |
| Mazdutide | 2259884-03-0 | Purity >98.0%, Lipidated | $320 - $480 / g | $210 - $310 / g | Direct Quote | Dual GLP-1/Glucagon Body Weight Control |
*Note on Pricing & Currency Policy: Quotes are denominated in USD to mitigate volatility in the PKR exchange rate. Flexible settlement mechanisms, including LC terms, CAD (Cash Against Documents), and escrow accounts, can be established for registered Pakistani corporate accounts subject to mutual compliance review.
Aligning raw active ingredient profiles with the most pressing non-communicable disease burdens across Punjab, Sindh, Khyber Pakhtunkhwa, and Balochistan.
With diabetes incidence touching nearly 30% in urban centers like Lahore and Faisalabad, localizing Retatrutide, Survodutide, and Mazdutide fills the massive clinical deficit left by expensive multinational brands.
Severe gastrointestinal motility disorders are prevalent across Pakistan due to dietary compositions. Linaclotide APIs allow domestic companies to launch cost-effective, high-stability oral capsules.
Pakistan's high-growth aesthetic and dermatology clinics demand premium GHK-Cu and regenerative peptides for post-procedural skincare, skin barrier restoration, and anti-aging treatments.
Beyond traditional injectable formats, Pakistani pharmaceutical innovators are actively exploring non-invasive peptide administration modalities. Oral delivery via Permeation Enhancers (such as SNAC - Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) and specialized sublingual formulations are generating profound interest among local R&D teams. By partnering with an API manufacturer with deep analytical expertise in solid-state characterization, crystalline polymorphism, and moisture adsorption isotherms, Pakistani pharmaceutical enterprises can pioneer proprietary drug delivery systems (DDS) that circumvent cold-chain dependency entirely.
Engineering temperature-resilient peptide APIs with validated cold-chain customs clearance procedures at Karachi Air Freight Unit (AFU) and Lahore International Terminal.
Utilizing high-performance Vacuum Insulated Panels (VIP) with integrated phase-change materials (PCM) maintaining 2°C to 8°C or dry ice (-20°C to -80°C) for up to 120 hours of total autonomy during regional transport.
Every commercial consignment exported to Pakistan includes NIST-traceable single-use USB/cellular temperature and humidity loggers, generating instant audit-ready reports upon arrival.
Providing advance electronic documents (Form 5 invoice endorsement, Certificate of Analysis, Packing List, Certificate of Origin, Safety Data Sheets) to eliminate ground delays at Pakistani customs checkpoints.
Retaining direct manufacturer pricing, verified structural integrity by MS, and guaranteed batch consistency across all production campaigns.
In-depth responses covering regulatory dossiers, analytical verification, cold-chain assurance, and financial transaction processing for Pakistani entities.
Partner with an integrated synthesis powerhouse capable of advancing your pipeline from R&D proof-of-concept to commercial vial production under full cGMP conditions.